cDNA microarray analysis of gene expression in pathologic stage IA nonsmall cell lung carcinomas

Cancer

Volumn 97, Issue 11, 2003, Pages 2798-2805

  Nakamura, Haruhiko ^a   Saji, Hisashi ^a   Ogata, Akihiko ^a   Hosaka, Makoto ^a   Hagiwara, Masaru ^a   Saijo, Takamoto ^a   Kawasaki, Norihito ^a   Kato, Harubumi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Cell adhesion molecule; Collagen; Cytokine; Gene chip; Lung carcinoma; Matrix metalloproteinase; Microarray; MRNA expression

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERFERON; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA HYBRIDIZATION; DNA MICROARRAY; DNA PROBE; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, COMPLEMENTARY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 0037844993     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11406     Document Type: Article

References (33)

1. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
2. Schena M, Shalon D, Davis R, Brown P. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-470.
3. Bowtell D. Options available-from start to finish-for obtaining expression data by microarray. Nat Genet. 1999;21 (suppl 1):25-32.
4. Cheung V, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G. Making and reading microarrays. Nat Genet. 1999; 21(suppl 1):15-19.
5. DeRisi J, Penland L, Brown P, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996;14:457-460.
6. Clarke P, Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol. 2001;62:1311-1336.
7. Available from URL: http://www.takara-bio.co.jp/member/ memberedit.php
8. Miedouge M, Devys A, Simon M, et al. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients. Tumour Biol. 2001;22:19-26.
9. McBride S, Walsh D, Meleady P, Daly N, Clynes M. Bromodeoxyuridine induces keratin protein synthesis at a post-transcriptional level in human lung tumour cell lines. Differentiation. 1999;64:185-193.
10. Dingemans A, Brakenhoff R, Postmus P, Giaccone G. Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest. 1997;77:213-220.
11. Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg. 1997;64:363-367.
12. Ylisirnio S, Hoyhtya M, Makitaro R, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res. 2001;7:1633-1637.
13. Thomas P, Khokha R, Shepherd F, Feld R, Tsao M. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol. 2000;190:150-156.
14. Bolon I, Devouassoux M, Robert C, Moro D, Brambilla C, Brambilla E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol. 1997;150:1619-1629.
15. Sasaki H, Yukiue H, Moiriyama S, et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001;101:242-247.
16. Wilson C, Heppner K, Labosky P, Hogan B, Matrisian L. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A. 1997;94:1402-1407.
17. Kawamata H, Kawai K, Kameyama S, et al. Overexpression of tissue inhibitor of matrix metalloproteinases (timp1 and timp2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer. 1995;63:680-687.
18. Kowalczyk A, Navarro P, Dejana E, et al. VE-cadherin and desmoplakin are assembled into dermal microvascular endothelial intercellular junctions: a pivotal role for plakoglobin in the recruitment of desmoplakin to intercellular junctions. J Cell Sci. 1998;111:3045-3057.
19. Bredin C, Sundqvist K, Hauzenberger D, Klominek J. Integrin dependent migration of lung cancer cells to extracellular matrix components. Eur Respir J. 1998;11:400-407.
20. Takenaka K, Shibuya M, Takeda Y, et al. Altered expression and function of beta-1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int J Oncol. 2000;17:1187-1194.
21. Retera J, Leers M, Sulzer M, Theunissen P. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol. 1998;51:891-894.
22. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789-4796.
23. Litwin M, Clark K, Noack L, et al. Novel cytokine-independent induction of endothelial adhesion molecules regulated by platelet/endothelial cell adhesion molecule (CD31). J Cell Biol. 1997;139:219-228.
24. Voura E, Chen N, Siu C. Platelet-endothelial cell adhesion molecule-1 (CD31) redistributes from the endothelial junction and is not required for the transendothelial migration of melanoma cells. Clin Exp Metastasis. 2000;18:527-532.
25. Salgia R, Li J, Ewaniuk D, et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999;18:67-77.
26. Fischer J, Schindel M, Stein N, et al. Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol. 1995;6:921-926.
27. Boldrini L, Calcinai A, Samaritani E, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer. 2000;83:480-486.
28. Shimomoto H, Hasegawa Y, Nozaki Y, et al. Expression of tumor necrosis factor receptors in human lung cancer cells and normal lung tissues. Am J Respir Cell Mol Biol. 1995;13:271-278.
29. Tran T, Kallakury B, Ambros R, Ross J. Prognostic significance of tumor necrosis factors and their receptors in non-small cell lung carcinoma. Cancer. 1998;83:276-282.
30. Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71:1095-1098.
31. Yuan A, Yu C, Luh K, Kuo S, Lee Y, Yang P. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 2002;20:900-910.
32. Bhattacharjee A, Richards W, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790-13795.
33. Garber M, Troyanskaya O, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784-13789.